
-
Pacira BioSciences NasdaqGS:PCRX Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Location: 5401 West Kennedy Boulevard, Tampa, FL, 33609, United States | Website: https://www.pacira.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.344B
Cash
493.6M
Avg Qtr Burn
N/A
Short % of Float
12.39%
Insider Ownership
1.80%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZILRETTA® (triamcinolone acetonide) Details Osteoarthritis Knee Pain | Approved Quarterly sales | |
Exparel (bupivacaine liposome) Details Post operative acute pain | Approved Quarterly sales | |
Exparel (bupivacaine liposome) Details Post operative acute pain | Approved Quarterly sales | |
PCRX-201 (enekinragene inzadenovec) Details Knee osteoarthritis | Phase 2 Data readout | |
PCRX-301 (FX301) (NaV1.7 inhibitor) Details Post operative acute pain , Pain | Failed Discontinued |